Therapy Areas: Oncology
Natera acquires Foresight Diagnostics to expand MRD capabilities
5 December 2025 - Cell-free DNA testing company Natera Inc (NASDAQ:NTRA) announced on Friday that it has acquired Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) det...
FDA clears Bristol Myers Squibb's Breyanzi as first CAR T therapy for relapsed or refractory marginal zone lymphoma
5 December 2025 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced late Thursday that it has received US Food and Drug Administration (FDA) approval for Breyanzi (lisocabtagene mara...
OncoHost named Gold Winner in 2025 Merit Awards for Healthcare
5 December 2025 - OncoHost, a technology company focused on transforming the approach to precision oncology through proteomics and AI, announced on Thursday that it has been honoured as a Gold Winner ...
Innovent Biologics and Takeda sign global strategic partnership
5 December 2025 - Chinese biopharmaceutical company Innovent Biologics (HKEX: 01801) announced on Thursday that it has entered into a global strategic collaboration with Japan-based Takeda (TSE: 4502,...
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
5 December 2025 - TransThera Sciences Inc, a China-based, clinical-stage biopharmaceutical company, on Thursday reported the publication of clinical results from a US-based Phase 2 trial assessing tin...
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
4 December 2025 - Orano Med, a subsidiary of the Orano group with a focus on nuclear medicine, announced on Thursday that its collaboration with Swiss biotechnology company Roche (SIX: RO, ROG; OTCQX:...